PRPO|Precipio Inc|Price:20.060|Chg%:-0.31

More Details of Precipio Inc Company

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Precipio Inc Info



Ticker SymbolPRPO

Company namePrecipio Inc

IPO dateJul 18, 2000

CEODanieli (Ilan S)

Number of employees54

Security typeOrdinary Share

Fiscal year-endJul 18

Address4 Science Park

CityNEW HAVEN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code06511

Phone12037877888

Websitehttps://www.precipiodx.com/

Ticker SymbolPRPO

IPO dateJul 18, 2000

CEODanieli (Ilan S)

Company Executives of Precipio Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Ilan S. Danieli

Chief Executive Officer, Founder, Director

--

Dr. Jeffrey Cossman, M.D.

Independent Director

--

Mr. David S. Cohen

Independent Director

--

Ms. Kathleen D. Laporte

Independent Director

--

Dick Sandberg ,

Independent Chairman of the Board

--

Mr. Ahmed Zaki Sabet

Chief Operations Officer

--

Mr. Ronald A. (Ron) Andrews, Jr.

Independent Director

--

Dr. Ayman A. Mohamed, M.D.

Chief Technology Officer

--

Mr. Matthew Gage

Chief Financial Officer

--

Ms. Christina R. Valauri

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Ilan S. Danieli

Chief Executive Officer, Founder, Director

--

Dr. Jeffrey Cossman, M.D.

Independent Director

--

Mr. David S. Cohen

Independent Director

--

Ms. Kathleen D. Laporte

Independent Director

--

Dick Sandberg ,

Independent Chairman of the Board

--

Mr. Ahmed Zaki Sabet

Chief Operations Officer

--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Third party payers

3.32M

48.19%

Medicare

2.79M

40.49%

Other

721.00K

10.47%

Contract diagnostics

43.00K

0.62%

Medicaid

11.00K

0.16%

Self-pay

4.00K

0.06%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Third party payers

3.32M

48.19%

Medicare

2.79M

40.49%

Other

721.00K

10.47%

Contract diagnostics

43.00K

0.62%

Medicaid

11.00K

0.16%

Self-pay

4.00K

0.06%

Shareholding Stats

Updated: Sun, Feb 1

Shareholders

Shareholder Types

Shareholders

Proportion

AMH Equity, Ltd.

8.56%

Eklund (David A)

4.81%

Topline Capital Management, LLC

3.72%

Cohen (David Seth)

3.10%

BlackRock Institutional Trust Company, N.A.

1.65%

Other

78.17%

Shareholders

Proportion

AMH Equity, Ltd.

8.56%

Eklund (David A)

4.81%

Topline Capital Management, LLC

3.72%

Cohen (David Seth)

3.10%

BlackRock Institutional Trust Company, N.A.

1.65%

Other

78.17%

Shareholder Types

Shareholders

Proportion

Hedge Fund

13.02%

Individual Investor

12.11%

Investment Advisor

5.55%

Investment Advisor/Hedge Fund

0.98%

Other

68.35%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

26

342.90K

19.57%

+87.45K

2025Q3

24

199.00K

12.29%

+26.19K

2025Q2

39

319.42K

21.11%

+23.29K

2025Q1

41

305.07K

20.32%

+66.28K

2024Q4

41

257.51K

17.37%

+21.31K

2024Q3

43

252.17K

17.06%

+16.33K

2024Q2

43

225.77K

15.35%

+14.07K

2024Q1

44

184.55K

13.08%

-29.31K

2023Q4

43

211.34K

15.03%

-9.34K

2023Q3

42

197.75K

14.39%

-78.27K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

AMH Equity, Ltd.

150.00K

8.56%

+18.90K

+14.42%

Oct 20, 2025

Eklund (David A)

84.25K

4.81%

+84.25K

--

Jul 25, 2024

Topline Capital Management, LLC

65.10K

3.72%

+65.10K

--

Sep 30, 2025

Cohen (David Seth)

53.69K

3.06%

+746.00

+1.41%

Oct 15, 2025

BlackRock Institutional Trust Company, N.A.

28.91K

1.65%

--

Sep 30, 2025

The Vanguard Group, Inc.

20.19K

1.15%

+2.54K

+14.41%

Sep 30, 2025

Sandberg (Richard A)

25.18K

1.44%

+17.95K

+248.20%

Apr 21, 2025

Evernest Financial Advisors, LLC

21.00K

1.2%

+21.00K

--

Sep 30, 2025

Andrews (Ronald Asbury)

15.80K

0.9%

+568.00

+3.73%

Oct 15, 2025

Cossman (Jeffrey M.D.)

15.34K

0.88%

+597.00

+4.05%

Oct 15, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

DFA Dimensional US Sustainability Core 1 ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Sep 21, 2023

Merger

20→1

Sep 21, 2023

Merger

20→1

Sep 21, 2023

Merger

20→1

Sep 21, 2023

Merger

20→1

Date

Ex-dividend Date

Type

Ratio

Sep 21, 2023

Merger

20→1

Sep 21, 2023

Merger

20→1

Sep 21, 2023

Merger

20→1

Sep 21, 2023

Merger

20→1